Biocon Limited has informed the Exchange regarding a press release dated September 18, 2025, titled "Biocon Biologics Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases".
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon Limited has shared a press release about its subsidiary Biocon Biologics' product Yesafili (aflibercept), a biosimilar used to treat advanced retinal diseases, being included in Ontario's public funding program in Canada. This means the treatment will now be reimbursed by the Ontario government, making it accessible to a wider patient base. Ontario is Canada's most populous province, making this a significant commercial milestone. The move follows similar public funding decisions in other regions and reflects growing acceptance of biosimilars in the Canadian healthcare system.
Positive for Biocon's revenue from its biologics business, as public reimbursement in a key Canadian province should drive higher sales volumes of Yesafili. Strengthens the global commercial footprint of Biocon Biologics and validates the company's biosimilar strategy, likely to be viewed favorably by investors.